Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the ... conjunction with diet and exercise to enhance glycemic control in persons with type 2 diabetes.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk’s Ozempic ... to diet and exercise to improve glycemic control in adults with T2D.

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...